Innovations in CKD Treatment for Diabetic Patients

This chapter explores recent advancements in pharmacologic therapies for chronic kidney disease (CKD) related to diabetes, focusing on the role of RAS inhibitors and new classes of medications like SGLT2 and GLP-1 receptor agonists. It highlights their significant clinical benefits in reducing the risks of CKD progression, heart failure, and mortality, emphasizing their importance in current treatment guidelines.